Question to the Foreign, Commonwealth & Development Office:

To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, if he will make it his policy to support (a) low and (b) middle income countries issuing compulsory licenses for the HIV prevention tool lenacapavir.

Lenacapavir could play a critical role in the global fight against HIV but only when it is available and affordable in countries that need it. We strongly supported Unitaid's decision to invest £17 million to accelerate access to Lenacapavir through market-shaping grants.

As Lord Collins stated in Parliament on 18 November at the HIV APPG roundtable, we welcome Gilead's bilateral voluntary licensing agreements with six generic manufacturers to make and sell generic Lenacapavir in 120 resource-limited countries, and their commitment to provide Lenacapavir at non-profit pricing in sub-Saharan Africa.

In combination with our market-shaping interventions, this will help accelerate access to this potentially groundbreaking tool.